Home » Stocks » ESPR

Esperion Therapeutics, Inc. (ESPR)

Stock Price: $27.55 USD 0.21 (0.77%)
Updated November 24, 4:00 PM EST - Market closed
After-hours: $27.25 -0.30 (-1.09%) Nov 24, 5:20 PM

Stock Price Chart

Key Info

Market Cap 768.00M
Revenue (ttm) 218.89M
Net Income (ttm) -101.02M
Shares Out 27.88M
EPS (ttm) -3.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $27.55
Previous Close $27.34
Change ($) 0.21
Change (%) 0.77%
Day's Open 27.36
Day's Range 27.30 - 28.47
Day's Volume 1,048,181
52-Week Range 23.90 - 76.98

More Stats

Market Cap 768.00M
Enterprise Value 730.16M
Earnings Date (est) Feb 24, 2021
Ex-Dividend Date n/a
Shares Outstanding 27.88M
Float 23.01M
EPS (basic) -3.70
EPS (diluted) -3.66
FCF / Share -2.43
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.06M
Short Ratio 20.09
Short % of Float 43.72%
Beta 1.76
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.51
PB Ratio 86.52
Revenue 218.89M
Operating Income -84.79M
Net Income -101.02M
Free Cash Flow -67.49M
Net Cash 37.84M
Net Cash / Share 1.36
Gross Margin -12.45%
Operating Margin -38.74%
Profit Margin -46.20%
FCF Margin -30.83%
ROA -20.94%
ROE -260.79%
ROIC -67.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (11)

Buy 7
Overweight 0
Hold 3
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

(175.54% upside)
Current: $27.55
Target: 75.91
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit148--------
Operating Income-93.10-205-169-76.15-50.04-36.22-22.76-10.20-10.16
Net Income-97.17-202-167-74.98-49.78-36.38-26.09-11.74-10.82
Shares Outstanding27.0926.7523.9322.5422.0216.377.890.320.30
Earnings Per Share-3.59-7.54-6.98-3.33-2.26-2.22-3.31-36.31-36.22
Operating Cash Flow-70.34-149-131-47.73-38.16-32.02-18.11-10.81-9.07
Capital Expenditures-0.95-0.15-0.02-0.09-0.30-0.860.17-0.01
Free Cash Flow-71.29-149-131-47.82-38.46-32.88-17.94-10.81-9.06
Cash & Equivalents20213620021221210660.066.511.57
Total Debt134-1.052.734.294.87-22.776.90
Net Cash / Debt67.6013619920920810160.06-16.26-5.33
Book Value19.9579.1224522928713474.09-41.36-30.03
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Esperion Therapeutics, Inc.
Country United States
Employees 193
CEO Tim M. Mayleben

Stock Information

Ticker Symbol ESPR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ESPR
IPO Date June 26, 2013


Esperion Therapeutics, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.